Genexine said Monday that I-Mab Biopharma, a Chinese biopharmaceutical company, has received approval from the China National Drug Administration (CNDA) to go ahead with phase 1 clinical trials for GX-G6, a persistent type diabetes treatment.

The treatment, named TJ103 in China, is a recombinant glucagon-like peptide (GLP-1) that treats patients whose insulin is not secreted in the body or whose cells do not respond to insulin.

Using the company’s original hyFc technology the treatment only requires patients to administer the drug once a week or twice a month, which is a drastic improvement from other first generation treatments that needed patients to apply the pills twice a week. The company has also confirmed the treatment’s superior safety profile in the phase I clinical trials conducted in Germany.

I-Mab is a specialized biopharmaceutical development company which is experiencing rapid growth and has a wide range of biopharmaceutical pipelines, including immunosuppressive drugs. The company has also recently acquired other various treatments from Genexine such as HyLeukin-7, which is an immuno-oncology agent, comprised of an engineered Interleukin-7 molecule.